CurveBeam AI Valuation

Is CVB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CVB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CVB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CVB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVB?

Key metric: As CVB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CVB. This is calculated by dividing CVB's market cap by their current revenue.
What is CVB's PS Ratio?
PS Ratio	6.1x
Sales	AU$6.53m
Market Cap	AU$39.56m

CVB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.5x
Enterprise Value/EBITDA	-2.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CVB's PS Ratio compare to its peers?

The above table shows the PS ratio for CVB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.2x
NTI Neurotech International	22.5x	44.7%	AU$71.4m
MX1 Micro-X	2.4x	38.2%	AU$36.6m
CDX CardieX	2.4x	54.8%	AU$30.9m
EYE Nova Eye Medical	1.5x	26.3%	AU$34.4m
CVB CurveBeam AI	6.1x	45.9%	AU$39.6m

Price-To-Sales vs Peers: CVB is good value based on its Price-To-Sales Ratio (6.1x) compared to the peer average (7.2x).

Price to Sales Ratio vs Industry

How does CVB's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
SDI SDI	1.1x	5.4%	US$79.56m
AHC Austco Healthcare	1.5x	n/a	US$56.19m
SOM SomnoMed	0.6x	9.0%	US$35.81m
CMP Compumedics	1x	n/a	US$34.04m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CVB is expensive based on its Price-To-Sales Ratio (6.1x) compared to the Australian Medical Equipment industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is CVB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.1x
Fair PS Ratio	4.7x

Price-To-Sales vs Fair Ratio: CVB is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Doctor Care Anywhere Group

AU$23.5m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

-4.5%

33.3%

Cogstate

AU$166.4m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.96

-2.5%

-36.9%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

-22.2%

n/a